• letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Immunomedics From: globenewswire.com Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published on NEJM.org as part of the February 21 print issue of the New England ...
    The post Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine appeared first on Let Life Happen.